Craig-Hallum Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alexander Nowak maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowers the price target from $74 to $50.
June 13, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Craig-Hallum analyst Alexander Nowak maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowers the price target from $74 to $50.
The news of Craig-Hallum maintaining a Buy rating on Tandem Diabetes Care is positive for the stock. However, the lowering of the price target from $74 to $50 may create uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100